Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012881 | 0.85 | TAAR1 (0.55) | TAAR1ACHERIPK1SIGMAR1KDM4E | |
| SCHEMBL18892527 | 0.83 | TAAR1 (0.54) | TAAR1ACHERIPK1SIGMAR1KMT2A | |
| SCHEMBL18316992 | 0.83 | TAAR1 (0.65) | TAAR1RIPK1SIGMAR1PTGESKMT2A | |
| SCHEMBL2018753 | 0.81 | TAAR1 (0.55) | TAAR1SIGMAR1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2097870 | 0.81 | NPY5R (0.56) | TAAR1KMT2A | |
| SCHEMBL16297341 | 0.80 | TAAR1 (0.50) | TAAR1ACHERIPK1SIGMAR1KMT2A | |
| SCHEMBL8586151 | 0.78 | CCR6 (0.42) | ACHEKMT2AALDH1A1 | |
| SCHEMBL552436 | 0.76 | TAAR1 (1.00) | TAAR1ACHESIGMAR1 | |
| SCHEMBL6378 | 0.75 | TAAR1 (0.53) | TAAR1PTGESMAOB | |
| SCHEMBL29970923 | 0.75 | TAAR1 (0.53) | TAAR1PTGESMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | TAAR1 4723/4885ACHE 2300/4885RIPK1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.